Ptc Therapeutics (PTCT) Share-based Compensation (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Share-based Compensation of $206.8 million for Q2 2026, up 1015.25% year-over-year from $18.5 million in Q2 2025, and down 10.75% quarter-over-quarter from $231.7 million in Q1 2026.
Ptc Therapeutics (PTCT) Share-based Compensation (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Share-based Compensation history runs 15 years deep, the most recent figure standing at $206.8 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 1015.25% year-over-year to $206.8 million; the TTM figure through Jun 2026 stood at $206.8 million (up 180.99% YoY), while the FY2025 annual figure was $129.8 million, up 31.11% from the prior year.
- Share-based Compensation for Q2 2026 stood at $206.8 million, down from $231.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $231.7 million in Q1 2026, with the low at $17.2 million in Q4 2024.
- The 5-year median for Share-based Compensation is $26.6 million (2022), against an average of $46.1 million.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation sank 36.22% in 2024, then surged 1182.95% in 2026.
- Ptc Therapeutics' Share-based Compensation stood at $27.3 million in 2022, then dropped by 1.47% to $26.9 million in 2023, then sank by 36.01% to $17.2 million in 2024, then increased by 7.42% to $18.5 million in 2025, then jumped by 1016.75% to $206.8 million in 2026.
- Business Quant data shows PTCT's Share-based Compensation at $206.8 million in Q2 2026, $231.7 million in Q1 2026, and $18.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 206.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 206.80 Mn |
| Jun 30, 2026 | 206.80 Mn |
| Mar 31, 2026 | 23.42 Mn |
| Mar 31, 2026 | 23.42 Mn |
| Dec 31, 2025 | 18.52 Mn |
| Dec 31, 2025 | 18.52 Mn |
| Sep 30, 2025 | 19.43 Mn |
| Sep 30, 2025 | 19.43 Mn |
| Jun 30, 2025 | 18.54 Mn |
| Jun 30, 2025 | 18.54 Mn |
| Mar 31, 2025 | 18.06 Mn |
| Mar 31, 2025 | 18.06 Mn |
| Dec 31, 2024 | 17.24 Mn |
| Dec 31, 2024 | 17.24 Mn |
| Sep 30, 2024 | 19.76 Mn |
| Sep 30, 2024 | 19.76 Mn |
| Jun 30, 2024 | 19.24 Mn |
| Jun 30, 2024 | 19.24 Mn |
| Mar 31, 2024 | 18.38 Mn |
| Mar 31, 2024 | 18.38 Mn |